This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • 2015
  • /
  • 09
  • /
  • Cardioband Mitral Reconstruction System receives C...
Drug news

Cardioband Mitral Reconstruction System receives CE mark approval in EU- Valtech Cardio

Read time: 1 mins
Last updated:15th Sep 2015
Published:15th Sep 2015
Source: Pharmawand

Valtech Cardio announced it has received CE Mark approval for its Cardioband Mitral Reconstruction System, a proprietary, implantable mitral reconstruction device with a transfemoral, transseptal delivery system for mitral valve repair in Heart Surgery.

The designation was based on the results of a multicenter feasibility trial that demonstrated the safety and effectiveness of Cardioband in mitral valve repair. Results of the study demonstrated that Cardioband is a highly effective first-line treatment option for reducing mitral regurgitation (MR) and improving quality of life scores. In a multicenter feasibility trial including more than 50 patients, Cardioband was shown to significantly reduce annular size, with significant improvement in MR. After six months of follow-up, 82% of patients (n = 22) were categorized in NYHA Class I-II, with significant improvement of quality of life (Minnesota Living With Heart Failure Questionnaire) score of 38 to 18 [p<0.05]; and had six-minute walk test score of 250 to 322 [p><0.05]). at 12 months' follow-up, 94% of patients (n="17)" had sustained mr less than or equal to 2+.>

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.